Real World Data: The future of clinical decisions

by Carlos Giner | May, 22 2019

In the middle of the information era, the Digital Health sector is experiencing a market shift in which the use of Real World Data (RWD) acquisition practices is growing. The role of RWD and RWE (Real World Evidence) has been increasing when it comes to clinical decision making, becoming useful for healthcare providers, medical product developers, or even the FDA itself. Persei vivarium works constantly to meet this increasing need through Digital Health solutions that help provide more complete and valuable insights based on Real World Data.

In order to understand the importance of these kinds of solutions, it is necessary to define Real World Data (RWD), as well as Real World Evidence (RWE).

According to the FDA, Real World Data are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. By analyzing these data sets, it is possible to get valuable insights known as Real World Evidence. So RWD would be the information collected (mainly from daily clinical practice), while the insights based on that information would be RWE.

At this point, we have not yet mentioned the sources of this data. That is actually one of the interesting features of this kind of data; there are many ways of getting it, but some of the most common ones are electronic health records (EHRs), disease/patient registries, patient-generated data, or data gathered from other sources that can provide information about health status. Moreover, RWD can also be obtained from devices such as smartphones or wearables. This represents a huge potential for Digital Health, since the interconnectivity of devices will continue to grow in the years to come.

At Persei vivarium, we are contributing to this revolution by developing products such as Caaring® (patient platform), ClinicaaL® (healthcare professional platforms) and ReseaArch® (researcher’s platform) that enable the capture and management of RWD on an unprecedented geographical scale. Our innovative approach allows the analysis of daily clinical practice and patient experience in order to understand how diseases are diagnosed, what the treatment  indications are, and what the patient experiences throughout the continuum of care.


Carlos Giner

Carlos Giner

Business Development

Persei vivarium